ANG LI to Rivaroxaban
This is a "connection" page, showing publications ANG LI has written about Rivaroxaban.
Connection Strength
0.627
-
Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States. Thromb Res. 2019 Aug; 180:37-42.
Score: 0.589
-
Direct oral anticoagulant- versus vitamin K antagonist-related gastrointestinal bleeding: Insights from a nationwide cohort. Am Heart J. 2019 10; 216:117-124.
Score: 0.037